Abstract: The invention provides formulations for oral delivery of a therapeutic agent wherein the formulation comprises a kappa opioid receptor agonist, an oligosaccharide stabilizing agent and an optional absorption enhancer. The kappa opioid receptor agonist may be coated with, embedded in or mixed with an oligosaccharide, such as trehalose. Also provided are capsules containing the oral formulations of the kappa opioid receptor agonists, the oligosaccharide and the absorption enhancer of the invention. The invention further provides methods of manufacture of the formulations and methods of their use for the prophylaxis, inhibition and treatment of variety of kappa opioid receptor-associated diseases and conditions such as pain, pruritus and inflammation. The methods of use include administering to the mammal the formulation of the kappa opioid receptor agonist, oligosaccharide and optional absorption enhancers.
Abstract: A process prepares a polymer-coated hard shell capsule, suitable as container for pharmaceutical or nutraceutical biologically active ingredients. The hard shell capsule can include a body and a cap. In the closed state, the cap overlaps the body either in a pre-locked state or in a final-locked state. The hard shell capsule can be provided in the pre-locked state and spray-coated with a coating solution, suspension, or dispersion that includes a polymer or a mixture of polymers to create a coating layer which covers the outer surface of the hard shell capsule in the pre-locked state.
Type:
Grant
Filed:
November 14, 2018
Date of Patent:
May 14, 2024
Assignee:
Evonik Operations GmbH
Inventors:
Ashish Guha, Vishal Kaneria, Vinay Jain, Shraddha Joshi, Miriam Robota, Felix Hofmann, Marcel Arndt, Hans Bär
Abstract: Enteric softgel capsules comprise a fill material and an enteric shell composition, characterized in that the enteric nature of the capsules may be achieved without an enteric coating or added conventional enteric polymers.
Abstract: Disclosed is the use of a water-soluble realgar solid dispersion in the preparation of an erythroid differentiation inducer for bone marrow hematopoietic stem cells and/or bone marrow hematopoietic progenitor cells. The water-soluble realgar solid dispersion is prepared from raw materials comprising 1 part by weight of realgar, 1-20 parts by weight of a polymer, and 0-5 parts by weight of a surfactant. The water-soluble realgar solid dispersion can induce bone marrow hematopoietic stem and/or progenitor cells to be differentiated into red blood cells, promote the accumulation of red blood cells in bone marrow cells, effectively alleviate the decrease in the number of red blood cells caused by the suppression of the erythroid differentiation of bone marrow hematopoietic stem and/or progenitor cells, improve anemia caused by hematopoietic failure, and protect bone marrow cells from the killing effect.
Type:
Grant
Filed:
April 11, 2019
Date of Patent:
May 7, 2024
Assignee:
INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES
Inventors:
Haiyan Xu, Jian Liu, Tao Wang, Bing Han, Jie Meng, Tao Wen
Abstract: Pharmaceutical compositions comprising an immediate release component comprising 4-((L-valyl)oxy)butanoic acid and a modified release component comprising 4-((L-valyl)oxy)butanoic acid and the pharmacokinetics of 4-((L-valyl)oxy)butanoic acid and ?-hydroxybutyrate following oral administration of the pharmaceutical compositions is disclosed.
Type:
Grant
Filed:
October 26, 2022
Date of Patent:
April 2, 2024
Assignee:
XWPHARMA LTD.
Inventors:
Daniel M. Canafax, William W. Xiang, Leonard Blum, Jia-Ning Xiang
Abstract: The present application relates to a pregabalin sustained release composition, comprising: (a) an active ingredient; (b) a matrix-forming agent; (c) a swelling agent; (d) a gelling agent; and optionally a filler. The pregabalin sustained release composition provided in the present application can rapidly swell in volume when exposed to aqueous medium until exceeding the dimeter of human gastric pyloric (13 mm). It thereby prolongs the gastric emptying time to increase the retention time of pregabalin in the stomach and enhances absorption of pregabalin in the small intestine and ascending colon. Moreover, the pregabalin sustained release composition provided herein achieves a sustained release for 24 h, which allows QD (once a day) administration, reduces administration number, and improves patient compliance.
Type:
Grant
Filed:
June 12, 2019
Date of Patent:
March 26, 2024
Assignee:
BEIJING TIDE PHARMACEUTICAL CO., LTD.
Inventors:
Zhaolu Zhu, Yun Wu, Di Lu, Yanping Zhao, Liying Zhou, Yanan Liu
Abstract: Compositions, systems and methods of dispensing compositions for treating skin conditions, the compositions including an inorganic compound and having desirable viscosity, spreadability and foam drainage profiles.
Abstract: Pharmaceutical granulations having a functional coating surrounding a core containing 4-((L-valyl)oxy)butanoic acid are disclosed. The functional coatings provide for immediate release or modified release of 4-((L-valyl)oxy)butanoic acid. The pharmaceutical granulations can be used in oral pharmaceutical compositions.
Type:
Grant
Filed:
June 17, 2022
Date of Patent:
March 12, 2024
Assignee:
XWPHARMA LTD.
Inventors:
Sami Karaborni, Daniel M. Canafax, Jia-Ning Xiang, William W. Xiang, James Tien, Stefanie Thiel, Norbert Pollinger, Annette Grave
Abstract: The present invention provides pharmaceutical composition of immunosuppressive agent in oral suspension dosage form. The oral suspension composition comprises of immunosuppressive agent with other pharmaceutical excipients such as vehicle, suspending agent, solvent or cosolvent, preservative, sweetener, antifoaming agent, wetting agent, buffering agent and flavouring agent. The present invention oral suspension having improved stability, palatability with high dose of active ingredient. The present invention provides oral suspension with flavor that has masked bitter taste of the drug and eliminates difficulty of administration. Further, the present invention also provides a convenient, easy process for preparation thereof.
Abstract: Provided herein are stable amlodipine liquid formulations. Also provided herein are methods of using amlodipine liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
Abstract: A composition comprising particles formed of poly(diaminosulfide) and one or more leptospiral antigens, and methods of making and using the composition, are provided.
Type:
Grant
Filed:
December 11, 2020
Date of Patent:
February 20, 2024
Assignees:
University of Iowa Research Foundation, The United States of America, As Represented by The Secretary of Agriculture
Inventors:
Aliasger K. Salem, Emad I. Wafa, Sean M. Geary, Ned B. Bowden, Jennifer H. Wilson-Welder, David P. Alt
Abstract: Compositions for forming porous materials and three-dimensional objects, including fibers, films and coatings made from the materials are provided. Also provided are methods for forming the porous objects from the compositions. The compositions include a solvent, a polymer binder that is soluble in the solvent, and solid particles that are insoluble in the solvent. The solid particles include water-soluble salt particles that can be selectively dissolved from objects made from the compositions to render the resulting structures porous.
Type:
Grant
Filed:
November 27, 2018
Date of Patent:
February 13, 2024
Assignee:
NORTHWESTERN UNIVERSITY
Inventors:
Adam E. Jakus, Ramille N. Shah, Nicholas R. Geisendorfer
Abstract: Pharmaceutical compositions of 4-((L-valyl)oxy)butanoic acid and the pharmacokinetics of 4-((L-valyl)oxy)butanoic acid and ?-hydroxybutyric acid following oral administration of the pharmaceutical compositions to healthy subjects are disclosed.
Type:
Grant
Filed:
July 22, 2021
Date of Patent:
February 13, 2024
Assignee:
XWPHARMA LTD.
Inventors:
William W. Xiang, Jia-Ning Xiang, Daniel M. Canafax
Abstract: Described are sustained-release solid dosage forms of epigallocatechin gallate (EGCG) or aminosterol compositions. In one aspect of the invention the sustained-release solid dosage forms of EGCG or an aminosterol are capsules comprising a plurality of coated solid particulates. Another aspect of the invention relates to methods of inhibiting, ameliorating, reducing the likelihood of, delaying the onset of, treating or preventing an amyloid disorder, comprising the step of administering to a subject in need a therapeutically effective amount of the solid dosage form. In certain aspects, the amyloid disorder is Parkinson's Disease.
Type:
Grant
Filed:
January 12, 2022
Date of Patent:
January 30, 2024
Assignee:
Axial Therapeutics, Inc.
Inventors:
Ryan Barrett, Hitesh Bhagat, Anthony Stewart Campbell
Abstract: An insulin formulation and a method of preparing and using same. The insulin preparation includes insulin, oligosaccharide and sodium chloride at a ratio of 1:A:B (w:w:w respectively) with ranges of A and B are 1000-5000 and 10-50, respectively.
Type:
Grant
Filed:
September 6, 2022
Date of Patent:
January 30, 2024
Assignee:
Elgan Pharma Ltd
Inventors:
Michal Olshansky, Elena Ostrovsky, Stav Zeldis
Abstract: The present invention relates to the technical field of medicine and relates to an instant release pharmaceutical preparation of an anticoagulant and a preparation method therefor. The instant release pharmaceutical preparation of an anticoagulant comprises a vicagrel compound or a pharmaceutically acceptable form thereof, the preparation is a tablet or a capsule, the vicagrel or the pharmaceutically acceptable form thereof is provided at a suitable particle size, and the D90 thereof <50 ?m. With regard to the drug-containing particles obtained by the present invention, a pharmaceutical preparation formed therefrom exhibits rapid release characteristics in an in vitro dissolution test and exhibits considerable advantages in pharmacokinetics in vivo, showing a greater degree (AUC) and rate (Cmax) of drug absorption.
Abstract: The present disclosure relates to pharmaceutical compositions, including dosage forms, such as tablets or capsules, comprising venglustat, in free base, or pharmaceutically acceptable salt form, a diluent/filler and a lubricant, optionally in combination with one or more additional therapeutic agents, to processes for manufacture thereof, and to methods of use in the treatment or prevention of disease.
Type:
Grant
Filed:
July 23, 2021
Date of Patent:
January 2, 2024
Assignee:
GENZYME CORPORATION
Inventors:
Audrey Jeanjean, Danielle Combessis, David Rigal, Chris Ho, Pankaj Taneja
Abstract: A cosmetic composition with enhanced water resistance, color intensity and color retention after exposure to water is disclosed herein. The composition comprises a water dispersible film former component, a skin adhesion promoter component, a color enhancer component, and one or more colorants. The synergy of the components contributes to the improved attributes of the composition.